Phase III studies of investigational gantenerumab did not meet their primary endpoints of slowing clinical decline in early Alzheimer’s disease, the Roche Group said. Beta-amyloid removal also was lower than expected with the drug.
Read MorePhase III studies of investigational gantenerumab did not meet their primary endpoints of slowing clinical decline in early Alzheimer’s disease, the Roche Group said. Beta-amyloid removal also was lower than expected with the drug.
Read MoreSource: Advances in technologies to detect early signs of disease from a blood sample are helping doctors to identify the memory-robbing disorder more accurately and to screen participants more quickly for trials of potential treatments.
Read MoreGCG Global Healthcare are specialists in healthcare excellence. Driven by a desire to improve healthcare and clinical solutions for everyone – patients, medical professionals and facilities. We aim to foster a culture of excellence through collaboration with industry experts and thought leaders to deliver better outcomes.